Nov 21,2023 TOP STORY

Owkin expands reach of AI diagnostic for colorectal cancer through integration with Sectra

Owkin, a techbio company that uses artificial intelligence to discover and develop new and better drugs and diagnostics at scale, announced an integration with international medical imaging IT and cybersecurity company Sectra to integrate Owkin’s MSIntuit® CRC AI diagnostic into Sectra’s digital pathology solution. MSIntuit® CRC is the first CE-marked AI diagnostic for microsatellite instability (MSI) testing for colorectal cancer using digital H&E slides. It serves as a pre-screening tool for colorectal cancer patients that aims to streamline MSI testing, saving critical pathology resources by significantly reducing the proportion of patients that need to be fully screened by traditional methods. The announced integration makes it possible for Sectra users all around the world to integrate and use MSIntuit® CRC in a way that it becomes part of the pathologists' existing digital pathology workflow.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 16,2023

Blackford and contextflow Announce Commercial Partnership to Bring Comprehensive Chest CT Detection Software to Healthcare Providers

Blackford, the pioneering strategic AI platform and solutions provider, and contextflow announced a commercial partnership to bring contextflow’s ADVANCE Chest CT solution to healthcare professionals. Under the partnership, contextflow’s innovative technology will be integrated with Blackford’s advanced enterprise AI platform. Blackford provides healthcare professionals access to an extensive portfolio of medical AI solutions designed to drive clinical efficiency and improve patient outcomes. contextflow’s CE and UKCA marked technology, ADVANCE Chest CT, offers radiologists comprehensive computer-aided detection support for lung cancer, ILD, and COPD patients. The software detects, visualizes and quantifies nodules and lung disease patterns to enhance the speed and quality of radiology reports.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 20,2023

Tempus Welcomes City of Hope Comprehensive Cancer Center to Tempus+ Community

Tempus, a leader in artificial intelligence and precision medicine, today announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers represents over 30 medical centers that are leveraging the program to advance its research. “Tempus+ provides a platform for researchers to interrogate the complex molecular state of cancer. The data is invaluable in understanding cancer biology, especially the development of better prognostic and predictive biomarkers,” said Marwan Fakih, MD, Professor, Medical Oncology Division Head, GI Medical Oncology, Associate Director for Clinical Sciences. “This comprehensive database is easy to navigate and allows investigators from various institutes to generate hypothesis-generating data or to validate pilot data generated from prior limited data sets.”

#rwd

View Analyst & Ambassador Comments
Go to original news
Nov 16,2023

Lunit to Implement AI-Powered Chest Screening Solution in Five Major Saudi Hospitals

Lunit announced an expansion of its services in the Kingdom of Saudi Arabia. Under its recent contract, Lunit will deploy its AI solution, Lunit INSIGHT CXR, in five major hospitals across the Kingdom. Lunit INSIGHT CXR is designed to detect the ten most common lung abnormalities, including lung cancer, tuberculosis, and pneumonia. The hospitals that will benefit from this collaboration include: National Guard Hospital Riyadh, King Abdulaziz Medical City, Security Forces Hospital, Al Takhassusi Hospital and Al Moosa Specialist Hospital.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 17,2023

Researchers Take New AI Approach to Analyze Tumors

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue. The method, presented in the journal Nature Communications, could contribute to more personalised treatment of cancer patients. "We realised that the interpretation of tumour images is similar to the interpretation of satellite images and that the relationships between cells in a tissue are similar to the relationships between species in ecology," explains Jean Hausser, senior researcher at the Department of Cell and Molecular Biology, Karolinska Institutet, who led the research. "By combining techniques used in satellite imaging and ecology and adapting them for the analysis of tumour tissue, we have now been able to turn complex data into new insights into how cancer works." The next step is to apply the new method in clinical trials. The researchers are collaborating with a major cancer hospital in Lyon, France, to seek answers to why only some patients respond to cancer immunotherapy. In another collaboration with the Mayo Clinic in the US, they are investigating why some breast cancer patients don’t need chemotherapy.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Nov 16,2023 TOP STORY

Lunit receives $150M capital chip-in, doubles down on US market

Shareholders of KOSDAQ-listed Lunit have recently participated in the company's recent capital raise, paying-in $150 million to fund its development of "next-generation" products and further expansion in the West. In a company disclosure, Lunit shared that more than a third or about $52 million of its capital proceeds will go to building new AI cancer diagnostics and therapeutics; $38 million will be invested in its subsidiaries in the United States and Europe; $30 million will be used to invest in external startups; and $15 million each will go to global talent and labour recruitment and acquiring patents, licences and other intangible assets. A day before it announced its significant capital raise, Lunit disclosed that it received the US FDA approval for its AI 3D Breast Tomosynthesis (DBT) solution.

FUNDING FUNDING ROUND

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 14,2023 TOP STORY

ConcertAI Announces Agreement with Leading Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions

ConcertAI announced a multi-year strategic agreement with Memorial Sloan Kettering Cancer Center (MSK) focused on accelerating the development and deployment of Clinical AI algorithms and integrated imaging workflows for clinical trials and oncology clinical decision augmentation. MSK will use AI SaaS solutions from ConcertAI's Eureka Life Science AI Platform, powered by TeraRecon, to build, test, and deploy functionality leveraging semi-supervised learning data curation and annotation to facilitate the development of tumor detection, segmentation, and classification models for predicting tumor mutations and assessing cancer treatment response. By leveraging MSK's deep AI and radiology expertise, the two organizations will co-evolve a common architecture and set of robust workflows to materially change and enhance how medical images are processed, analyzed, and interpreted in both clinical trials and clinical care.

COLLABORATION PARTNERSHIP

#r&d

#clinical decision support

#rwd

View Analyst & Ambassador Comments
Go to original news
Nov 13,2023

Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology

Charles River Laboratories International and Aitia, a leader in the application of Causal AI and Digital Twins, announced a strategic agreement that gives Aitia access to Logica™, Charles River’s Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology. Aitia will deploy Logica across their portfolio of novel drug targets with the aim of creating and advancing drug candidates for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases and cancers, including prostate cancer and multiple myeloma. Additionally, Charles River and Aitia have signed a strategic partnership agreement, focused on the development of a patient-derived xenograft (PDX) Digital Twin to predict the best tumor models for in vivo oncology research. In drug discovery, Digital Twins enable the accurate simulation of gene and protein knockdowns at the individual patient level across patient cohorts to discover and genetically validate novel drug targets.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 15,2023 TOP STORY

COTA and Aetion partner to expand access to real-world data for oncology research

COTA has partnered with Aetion®, a global leader in real-world evidence (RWE) and analytics, to make it faster and easier to access fit-for-purpose datasets for research. By combining the power of the Aetion Evidence Platform® (AEP) with COTA’s clinically curated, multi-source oncology Vantage RWD assets, investigators will be able to streamline access to meaningful data so they can focus on the science instead. This collaboration enables Aetion and COTA to meet the needs of researchers requiring high-quality, clinically rich oncology data, for both liquid and solid tumor types.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Nov 15,2023

Tempus Announces Medicare Coverage for Tempus|xT Across Solid Tumor and Hematologic Malignancies

Tempus, a leader in artificial intelligence and precision medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor, and the Molecular Diagnostics Services Program (MolDx) has approved coverage for Tempus|xT, Tempus’ 648-gene DNA sequencing panel, for use in solid tumor and hematologic malignancies. xT is now covered for Medicare patients under the MolDx program for tumor-only as well as normal match sequencing in all solid tumors, and tumor sequencing for patients with myeloid and suspected myeloid malignancies. xT is a DNA sequencing panel that provides a comprehensive view of patients’ genomic profiles, equipping physicians to make informed treatment decisions.

#reimbursement

#ai/software

#genomic profiling

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY